Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00958893 · ClinicalTrials.gov registry record · Phase 2
An Extension Study Evaluating Safety and Efficacy of Proellex® In Women Who Have Previously Completed ZPU 003 Ext
A Phase 2 study, sponsored by Repros Therapeutics.
- Terminated
- Registry status
- Phase 2
- Development phase
- 4
- Enrollment target
NCT00958893: Clinical Trial Phase 2 study, sponsored by Repros Therapeutics.
NCT00958893 is a Phase 2 study that was terminated before completion, run by Repros Therapeutics. The registered enrollment target is 4 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (97% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00958893, a Phase 2 study, was terminated before completion, sponsored by Repros Therapeutics.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 4 participants
- Enrollment target
Study Summary
An open label, extension study for subjects completing the ZPU-003 Ext 1 study.
Interventions
- DRUG 25 mg Proellex
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 4 participants |
| Start Date | 2008-06 |
| Est. Completion | 2009-08 |
| Phase | Phase 2 |
Why NCT00958893 stopped before completion
NCT00958893 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 4 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (97% lower).
The record links to 0 conditions, and to 1 intervention - of which 25 mg Proellex is the first listed.
NCT00958893 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00958893 about?
NCT00958893 is a clinical study titled "An Extension Study Evaluating Safety and Efficacy of Proellex® In Women Who Have Previously Completed ZPU 003 Ext". An open label, extension study for subjects completing the ZPU-003 Ext 1 study.
What is the current status of trial NCT00958893?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 4 participants. The study started on 2008-06. Estimated completion is 2009-08.
What interventions are being tested in trial NCT00958893?
The interventions under investigation include: 25 mg Proellex (DRUG).
Who is sponsoring clinical trial NCT00958893?
This trial is sponsored by Repros Therapeutics, which has 50 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00958893's enrollment target sits among peer trials
4 2001st of 2000 the lowest of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia